KALA BIO (KALA) vs Propanc Biopharma (PPCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Propanc Biopharma is the larger company by market cap ($1.9 million vs $1.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KALA | PPCB |
|---|---|---|
| Share price | $2.71 | $1.78 |
| Market cap | $1.74M | $1.87M |
| 1-day change | -10.28% | +3.19% |
| EPS (TTM) | $-321.30 | $-95.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-26.98M | $-18.86M |
| 52-week high | $2,865.00 | $315.00 |
| 52-week low | $2.65 | $1.61 |
| Distance from 52-week high | -99.91% | -99.43% |
| Average volume | 52.52K | 188.66K |
| Shares outstanding | 644.66K | 1.05M |
| Employees | 6 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About KALA BIO
KALA stock →KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Propanc Biopharma
PPCB stock →Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
KALA vs PPCB FAQ
Which is bigger, KALA BIO or Propanc Biopharma?
Propanc Biopharma (PPCB) is larger, with a market capitalization of $1.87M compared with $1.74M for KALA BIO (KALA).
Are KALA BIO and Propanc Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.